BIIB Biogen Inc

Biogen is a biotechnology company focused on neurological and rare diseases, with a research pipeline spanning Alzheimer's disease, multiple sclerosis, and neuromuscular disorders. Sector: Healthcare.

Biogen Inc (BIIB) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

Through the lens of capital efficiency, ROIC is 10.14%, WACC is 4.79%, and the economic spread is 5.35%. On balance, ROIC edges above WACC, suggesting the company are value-creative in aggregate, if not dramatically so. Supporting metrics show ROE at 7.38% and ROA at 5.33%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company that is value-creative but with less room for execution slippage.

On a multiple basis, the company trades at trailing P/E of 20.15, forward P/E of 11.26, PEG of 3.42. Forward P/E is below trailing by a moderate margin, pointing to modest earnings expectations that support the current valuation without relying on outsized growth. The PEG reading is high enough to suggest the market is attributing significant optionality or quality premium to the company's underlying businesses. The company's weighted current ratio of 2.68 signals strong near-term financial resilience. The valuation setup is broadly consistent with a market that is pricing growth without being reckless about it — a balanced but not cautious stance.

The margin profile breaks down as follows: gross margin sits at 77.32%, operating margin at 26.75%, and free cash flow margin at 20.32%. The company's gross margin reflects businesses that retain a large share of revenue before overhead — a sign of genuine competitive insulation. Operating margins are solid, reflecting adequate cost control relative to the revenue base. The company's FCF margin is healthy, indicating solid cash conversion after capital expenditure needs. The full margin stack is constructive, with pricing power, operating leverage, and cash conversion largely aligned.

The growth and outlook picture reads as follows: TTM revenue growth of 2.22% indicating muted but still positive top-line momentum across the company. In parallel, analysts project moderate appreciation over the next 12 months based on current consensus targets. The gap between trailing fundamentals and forward expectations matters most at inflection points — and the current environment is not without those. For long-term holders, the central question is whether today's execution quality is a leading indicator of what's already priced into analyst targets. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

The data points reviewed collectively point toward a positive outcome if execution holds — the setup is favorable even accounting for the inherent uncertainty in forward estimates.

The analysis above draws from quantitative data only and does not constitute personalized financial advice. Investors should conduct independent research and consider professional guidance before acting on any information presented here.